Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Treasury Shares (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Treasury Shares for 3 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For Q4 2025, Treasury Shares rose 421.07% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, up 421.07%, while the annual FY2025 figure was $2.6 million, 421.07% up from the prior year.
  • Treasury Shares hit $2.6 million in Q4 2025 for Artiva Biotherapeutics, up from $1.3 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.6 million in Q4 2025 and bottomed at $22514.0 in Q4 2023.
  • Average Treasury Shares over 3 years is $1.2 million, with a median of $1.4 million recorded in 2025.
  • Year-over-year, Treasury Shares skyrocketed 2151.24% in 2024 and then soared 421.07% in 2025.
  • Artiva Biotherapeutics' Treasury Shares stood at $22514.0 in 2023, then surged by 2151.24% to $506845.0 in 2024, then skyrocketed by 421.07% to $2.6 million in 2025.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $2.6 million, $1.3 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.